BIOMAT Database Logo BIOMAT Database Logo

Long-acting injectable risperidone. 2004

Megan J Ehret, and Matthew A Fuller
Cleveland Department of Veterans Affairs Medical Center, 10000 Brecksville Rd., Brecksville, OH 44141-3204, USA.

OBJECTIVE To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of long-acting (LA) risperidone for the treatment of schizophrenia. METHODS Information was selected from PubMed (1965-July 2004). Applicable scientific posters were also used. METHODS All published information on risperidone LA was considered. Material providing a comprehensive description was considered. RESULTS Risperidone LA is the first long-acting, injectable atypical antipsychotic. It is dosed at 25-50 mg every 2 weeks. Adverse effects are similar to those seen with oral risperidone. A short-term study showed that risperidone LA is better than placebo in reducing the signs and symptoms of schizophrenia, and a long-term trial showed that stable schizophrenic patients can be switched from either oral or other injectable antipsychotic medications to risperidone LA. CONCLUSIONS Risperidone LA is efficacious and safe in the treatment of schizophrenia.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D018967 Risperidone A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA. R-64,766,R-64766,Risperdal Consta,Risperidal,Consta, Risperdal,R 64,766,R 64766,R64,766,R64766

Related Publications

Megan J Ehret, and Matthew A Fuller
Extrapyramidal syndrome and long-acting injectable risperidone.
April 2004, The American journal of psychiatry,
Megan J Ehret, and Matthew A Fuller
Initial dosing strategies for long-acting injectable risperidone.
August 2006, The Journal of clinical psychiatry,
Megan J Ehret, and Matthew A Fuller
Effects of Discontinuation of Paliperidone Long-Acting Injectable After Switching from Risperidone Long-Acting Injectable Switching.
August 2016, Psychopharmacology bulletin,
Megan J Ehret, and Matthew A Fuller
Comparative effectiveness of long-acting injectable risperidone vs. long-acting injectable first-generation antipsychotics in bipolar disorder.
June 2016, Journal of affective disorders,
Megan J Ehret, and Matthew A Fuller
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
June 2003, The American journal of psychiatry,
Megan J Ehret, and Matthew A Fuller
Long-acting injectable risperidone: an emerging tool in schizophrenia treatment.
December 2005, Journal of psychosocial nursing and mental health services,
Megan J Ehret, and Matthew A Fuller
[Pharmacoeconomic review of the use of injectable long-acting risperidone].
December 2005, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology,
Megan J Ehret, and Matthew A Fuller
Clinical review of a long-acting, injectable formulation of risperidone.
December 2004, Clinical therapeutics,
Megan J Ehret, and Matthew A Fuller
Evaluation of a treatment manual for risperidone long-acting injectable.
June 2007, Community mental health journal,
Megan J Ehret, and Matthew A Fuller
Long-acting injectable risperidone for control of agitation in dementia.
October 2006, The Journal of clinical psychiatry,
Copied contents to your clipboard!